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Tritiated reserpine binds to synaptic vesicles from bovine caudate with high affinity (edpp = 1.25 nM, 
B = 3.3 pmollmg protein). This interaction is both ATP~ependent and sensitive to the protonophores 
C”c”cP and nigericin, suggesting that a proton electrochemical gradient is required for binding. Dopamine, 
epinephrine, norepinephrine and serotonin all inhibit reserpine binding at concentrations imilar to those 
required for inhibition of dopamine uptake. Treatment with saponin to release vesicle contents results in 
complete loss of accumulated dopamine but retention of bound reserpine. These results indicate that 
reserpine binds to the catechohunine transport system of synaptic vesicles with high affinity and specificity. 
Reserpine Synaptic vesicle Dopamine uptake 
1. INTRODUCTION 2. MATERIALS AND METHODS 
A great deal of attention has been focused on the 
ATP-dependent uptake of catecholamines into 
synaptic vesicles and chromaffin granules, but lit- 
tle is known concerning the exact nature of the 
transport system itself. Reserpine is a specific com- 
petitive inhibitor of both systems [l-4] with Ki for 
inhibition of uptake over l-10 nM. Although the 
in vivo binding of reserpine to chromaffin granules 
had been shown in [5], the specific interaction of 
radiolabeled reserpine with the adrenal chromaffin 
granule in vitro was reported in [6]. ATP and 
magnesium were required for binding and the un- 
coupler FCCP inhibited the interaction. We now 
describe the ability of this compound to bind with 
high affinity and selectivity to synaptic vesicles 
isolated from bovine caudate nucleus and present 
evidence that this binding reflects specific labeling 
of sites involved in catecholamine transport. 
13H]Dop~ine (37 Cifmmol) and PH]reserpine 
(27.9 Ci/mmol) were obtained from New England 
Nuclear (Boston MA). All other materials were of 
the highest quality available. 
Abbreviations: APPNHP, @-imidoadenosine 5’ -triphos- 
phate; CCCP, carbonyl cyanide m-chlorophenyl hydra- 
zone; EGTA, ethyleneglycol bis @aminoethyl ether)- 
N,NN’,N’-tetraacetic acid; PMSF, phenylmethy1 
sulfonyl fluoride 
Bovine caudates were obtained within 10 min of 
death and homogenized immediately in ice cold 
0.32 M sucrose, 0.3 mM PMSF with 4 strokes by 
hand in a loose-fitting Dounce homogenizer before 
transportation to the laboratory. The inclusion of 
PMSF was essential to inhibit protease activity. 
Synaptic vesicles were prepared as in [7], and their 
identity confirmed by electron microscopy and 
determination of neurotransmitter content 181. 
They contained 50 -+ 15 pmol dopamine/mg vesi- 
cle protein, and analysis of their protein composi- 
tion by SDS-polyacrylamide gel electrophoresis 
under denaturing conditions demonstrated only 
very low levels of cont~ination by coated vesicles 
as judged by clathrin content. The final vesicle 
pellet was taken up in 50 mM KPO4 (pH 7.4), 
50 mM KCI, 10 mM NaCl, 2 mM EGTA at 
l-2 mg protein/ml and stored at - 80°C for up to 
1 week before use. Vesicles stored in this way ex- 
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hibited 70-80% of the dopamine uptake activity 
present in fresh vesicles. 
The association of tritiated reserpine and 
dopamine with synaptic vesicles was determined by 
a modification of the method in [9]. A 100 pl solu- 
tion containing 50 mM KP04 (pH 7.4), 50 mM 
KCl, 10 mM NaCl, 5 mM MgC12, 2 mM EGTA, 
0.02% ascorbate, 2 mM ATP, 5-4Opg protein 
and the appropriate concentration of radiolabeled 
reserpine or dopamine was incubated at 23°C for 
10 min, then chilled rapidly in an ice bath; 50 pl of 
the same buffer without ATP or magnesium, con- 
taining 5 mg/ml blue dextran-2000 was added and 
100 pl of the mixture placed on an 8 cm column of 
Sephadex G-50-80 in a Pasteur pipette and eluted 
with the same buffer. All fractions with blue color 
were collected in scintillation vials, 10 ml Aquasol 
(New England Nuclear) added and radioactivity 
determined. Specific binding of reserpine was 
taken as the difference between values obtained in 
the presence and absence of 2 ,uM non-radioactive 
reserpine. Similarly, specific dopamine uptake was 
defined as the difference between values obtained 
in the presence and absence of 100 nM cold reser- 
pine. Non-specific binding was ~25% of total 
binding for reserpine, and < 15% for dopamine. 
Unless otherwise indicated, binding activities are 
expressed as pmol/mg protein, determined as in 
WI. 
3. RESULTS Inhibition of reserpine binding and dopamine uptakea 
3.1. The catecholamine transporter binds 
reserpine with high affinity 
A Scatchard plot of the binding of tritiated 
reserpine to synaptic vesicles from bovine caudate 
in the presence of ATP is shown in fig.1. The 
ligand binds with an app. Kd of 1.3 nM, and 
3.3 pmol/mg protein are bound at saturation. This 
apparent affinity compares favorably with the ~CSO 
for inhibition of dopamine uptake by reserpine 
determined under the same conditions (4 nM), 
whereas the extent of binding at saturation is 
several orders of magnitude lower than that of 
dopamine uptake (l-2 nmol/mg protein; un- 
published). If reserpine interacts with the 
transporter responsible for uptake of 
catecholamines, dopamine and other members of 
this class of transmitters hould act as inhibitors of 
reserpine binding at concentrations comparable to 
Compound Dopamine Reserpine 
uptake binding 
ZCso GM) ZC50 (pM) 
Reserpine 0.004 0.003 
Tetrabenazine 0.007 0.020 
Harmaline 0.10 0.22 
Dopamine 3.7 6.6 
Epinephrine 3.6 8.4 
( - )Norepinephrine 4.1 9.2 
(&)Norepinephrine 8.8 17.7 
Serotonin 2.6 5.9 
a Assay mixtures contained 2 mM ATP and either 
1.5 nM reserpine or 3 PM dopatnine 
Z&J was defined as the concentration of inhibitor 
required for 50% inhibition of specific binding. Non- 
specific binding in the presence of all agents tested was 
equal to non-specific binding in the absence of agent 
I I I I 
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Fig.1. Scatchard plot of specific reserpine binding to 
bovine caudate synaptic vesicles in the presence of 2 mM 
ATP. Each point is the mean of 4 determinations f SD. 
Non-specific binding was linearly dependent on the 
concentration of radioactive ligand, and was ~25% of 
total binding at up to 12 nM. 
those required for inhibition of dopamine uptake. 
All such candidates tested exhibit inhibitory poten- 
cies in the micromolar range (table l), suggesting 
that amine uptake and reserpine binding occur by 
a common mechanism since these compounds also 
Table 1 
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inhibit dopamine uptake at similar concentrations. 
Inhibition of both dopamine uptake and reserpine 
binding by norepinephrine is also stereoselective 
(table 1). However, once reserpine is bound to 
vesicles, subsequent incubation with dopamine 
(10 mM), tetrabenazine (10 PM) or unlabeled 
reserpine (10 PM) for periods up to 2 h failed to 
displace bound radioactivity (not shown). 
3.2. Binding requires an electrochemical gradient 
generated by ATP hydrolysis 
Catecholamine uptake into synaptic vesicles and 
adrenal chromaffin granules depends on a 
transmembrane proton electrochemical gradient 
generated by a proton-translocating ATPase 
[ 1 l-l 31. Reserpine binding was also ATP- 
dependent (table 2) and of the 3 ATP analogs 
tested, only cu,,&methylene-ATP stimulated bind- 
ing. This finding suggests that a hydrolysable ter- 
minal phosphate may be required for activity and 
is consistent with the postulate that ATP must be 
hydrolyzed by the proton-translocating ATPase to 
generate the electrochemical gradient required for 
reserpine binding and amine transport. Additional 
evidence for this is provided by results obtained by 
Table 2 
Effects of uncouplers and nucleoside phosphates on 
reserpine binding 
Addition Rel. act.* 
None 0.05 f 0.01 
ATP (2 mM) 1.00 f 0.03 
a&Methylene-ATP (2 mM) 0.31 f 0.01 
fi,y-Methylene-ATP (2 mM) 0.05 f 0.02 
AMPPNP (2 mM) 0.05 f 0.01 
ADP (2 mM) 0.38 f 0.04 
AMP (2 mM) 0.01 f 0.03 
CTP (2 mM) 0.52 f 0.05 
GTP (2 mM) 0.90 * 0.03 
ITP (2 mM) 0.89 f 0.02 
UTP (2 mM) 0.86 f 0.01 
CCCP (0.1 CM) + ATP (2 mM) 0.04 f 0.02 
Nigericin (0.1 CM) + 
ATP (2 mM) 0.06 f 0.03 
* Relative activity is defined as the ratio of specific 
binding under test condition to specific binding in the 
presence of ATP alone; reserpine was 5 nM; each 
value is the mean of 3 determinations f SD 
the addition of the uncouplers nigericin and 
CCCP. Both act by short-circuiting the transmem- 
brane proton gradient, and both are potent in- 
hibitors of ATP-dependent reserpine binding 
(table 2). 
3.3. Binding can be distinguished from 
catecholamine uptake 
To determine whether reserpine is also 
transported into vesicles, samples were first in- 
cubated under the standard conditions, then in- 
cubated a second time with various concentrations 
of saponin at 0°C to release vesicle contents. As 
shown in fig.2, >90% of vesicle-associated reser- 
pine remained bound at up to 0.15% saponin, 
while almost all the accumulated dopamine was 
released by this detergent at 0.02%. Once bound, 
reserpine was also insensitive to subsequent reat- 
ment of the vesicles with CCCP alone or in com- 
bination with saponin. Conversely, prior incuba- 
tion with CCCP or saponin, treatments which 
should prevent generation of a transmembrane 
gradient during the binding reaction, abolished all 
high-affinity binding. 
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Fig.2. Effect of saponin treatment on accumulated 
dopamine and bound reserpine. Vesicles were incubated 
for 10 min at 23°C with either reserpine (e) or 
dopamine (0), cooled to 0°C. then incubated a second 
time in the presence of various concentrations of 
saponin (O’C, 10 min)‘before application to Sephadex 
columns. Relative activity was defined as the ratio of 
specific binding under the test condition to that observed 
in the absence of saponin. Each point is the mean of 4 
determinations with SD < 8%. 
33 
Volume 158, number 1 FEBS LETTERS July 1983 
4. DISCUSSION 
Reserpine inhibits catecholamine uptake into 
adrenal chromaffin granules [1,3] both com- 
petitively with substrates for transport [2] and ir- 
reversibly under normal conditions (41. Reserpine- 
sensitive, ATP-dependent transport has also been 
demonstrated in isolated platelet granules [14], 
synaptic vesicles from rat heart 1151 and brain 
19,113, and in each case the basic mechanism ap- 
pears to be the same. Previous findings with 
chromaffin granules imply operationally separable 
species responsible for generation of proton elec- 
trochemical potential (ATPase), and actual uptake 
of ~atecholamines (transporter) [16,21]. The com- 
petitive nature of reserpine inhibition, and the in- 
sensitivity of granule and vesicle ATFases to reser- 
pine, suggest that reserpine interacts with the 
transporter itself. Here, we have shown that reser- 
pine binds to synaptic vesicles with an apparent af- 
finity which is comparable to its potency as an in- 
hibitor of dopamine uptake. Moreover, other 
catechoiamines inhibit both reserpine binding and 
dopamine uptake at similar concentrations and, in 
the case of norepinephrine, in a stereoselective 
fashion. 
Although the observation that the capacity of 
synaptic vesicles for reserpine is but a small frac- 
tion of that for dopamine may be an indication 
that dopamine is transported to the interior of the 
vesicle, while reserpine only binds to the 
transporter, such evidence does not constitute con- 
vincing proof. In studies on the lactose carrier pro- 
tein [22,23] it was concluded that several com- 
pounds with high affinity for the carrier were ac- 
tively transported, but a high rate of passive efflux 
resulted in low levels of net accumulation at 
equilibrium [24]. Dopamine is also known to be 
subject to both active uptake into and efflux from 
chromaffin granules 1251. In the case of reserpine 
binding, however, the possibility of uptake into the 
vesicle interior may be dismissed since saponin 
treatment, which releases accumulated dopamine 
by permeabilizing the vesicle membrane [26], does 
not release bound reserpine (fig.2). 
The binding of several uptake inhibitors, in- 
cluding reserpine, to chromaffin granules has been 
described in [6,27,28]. Comparisons of affinities in 
the two systems may be significant, but the re- 
quisite information is not yet available to compare 
34 
binding capacities: while adrenal chromaffin 
granules are relatively homogeneous with respect 
to the transmitters they contain, this is not true for 
synaptic vesicles from striatum, which, in addition 
to catecholamines and serotonin are also involved 
in the accumulation of other transmitters. 
The ATP-dependence of reserpine binding 
described here most likely reflects a conforma- 
tional change in the transporter induced by the 
proton ele~roche~c~ gradient. Changes in app. 
&,, for the lactose carrier system in response to an 
electrochemical gradient [23,29] and the asym- 
metric, mutually exclusive biriding of bongkrekate- 
type and atractylate-type inhibitors to the 
mitochondrial ADP/ATP translocator [30] are but 
two examples of how alternate conformational 
states can affect the interaction of ligands with 
transport proteins. In the present instance, the gra- 
dient generated by ATP hydrolysis may affect the 
transporter by one or more of several different 
mechanisms. It may lead to the unmasking of a 
cryptic site on the outer surface of the vesicle, or 
increase the affinity of a site already available in 
the unenergized state. Another possibility is that 
such a gradient is required for irreversible move- 
ment of reserpine across the membrane to form a 
high-affinity complex with the transporter on its 
internal face, or within the bilayer itself. The latter 
possibility may well explain the reversal of reser- 
pine inhibition in chromaffin granules by washing 
with phospholipid vesicles [4]. 
Whether reserpine binding to the outer surface 
takes place in the absence of ATP, or if this ligand 
binds to sites on the inner surface of synaptic 
vesicles under any conditions is not yet known. 
Studies of reserpine binding in the absence of 
ATP, and exploration of the nature of conforma- 
tional changes in the transporter induced by the 
electrochemic~ gradient, are the subjects of on 
going investigations. 
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